Alka-Seltzer Plus needs more time to re-label
This article was originally published in The Tan Sheet
Executive Summary
Bayer HealthCare asks FDA for more time to change packaging for its cold and flu relief line to comply with a final rule for labeling acetaminophen products. Thirteen stock-keeping units under the Alka-Seltzer Plus brand will be unable to accommodate organ-specific warnings by the rule's effective date of April 29, Bayer says in a Feb. 16 1letter to the agency. The firm's VP of Regulatory Affairs Leonard Baum explains, "Bayer was forced to wait" for FDA's technical amendment of Nov. 25, 2009, which clarified that smaller immediate containers such as blister cards and sachets must bear liver injury and stomach bleeding warnings (2"The Tan Sheet" Nov. 30, 2009). Bayer asks for a 12-month deferral to re-label ASP foil pouches and stick packs, and a six-month deferral to re-label the companion cartons. A spokeswoman said the company has not yet heard from FDA
You may also be interested in...
FDA Requires Liver Injury Warning On Acetaminophen Stick Packs, Sachets
Acetaminophen products sold in stick packs and sachets must carry warnings about the risk of liver injury by April 29, 2010, a technical amendment to the final rule for internal analgesics says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.